Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting
Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…Abstract Number: 1826 • 2017 ACR/ARHP Annual Meeting
Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
Background/Purpose: Psoriatic arthritis (PsA) disease activity score (PASDAS) assessing multiple facets of PsA was demonstrated to distinguish treatment effect, perform better in statistical terms than…Abstract Number: 1930 • 2017 ACR/ARHP Annual Meeting
Interleukin 1β Decreases Capacity for Repair Human Cartilage Lesions By Mesenchymal Stromal Cells on Collagen/Proteoglycan Scaffolds
Background/Purpose: There is controversy about the effect of catabolic cytokines in regenerative medicine. The purpose of this study was to evaluate the effect of interleukin…Abstract Number: 1936 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Blocks T Cell-Mediated Osteogenic Differentiation of Periosteal Stem Cells: Coupling Pathological Bone Formation to IL-17A and IL-17F Signaling
Background/Purpose: Structural tissue damage, as a result of pathological bone formation, is a major cause of disability in spondyloarthritis (SpA). A paucity of in vitro…Abstract Number: 2422 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA) Synovial Fluid Treg Cells Secrete IL-17 and at the Same Time Are Potent Suppressors of Tresp Cell Proliferation, TNF-α and Interferon γ Production
Background/Purpose: IL-17-expressing FoxP3 regulatory T cells have been described, and their suppressive capacity has been questioned. An inflammatory environment seems to favor IL-17 secretion by…Abstract Number: 2728 • 2017 ACR/ARHP Annual Meeting
Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients
Background/Purpose: Behcet's disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear.…Abstract Number: 31 • 2017 ACR/ARHP Annual Meeting
Single Cell Analysis Revealed That the Response to Cyclophosphamide Therapy Is Regulated By B Cells in Systemic Sclerosis-Associated Interstitial Lung Disease
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of several organs. SSc-associated interstitial lung disease (ILD) is a frequent and severe complication…Abstract Number: 85 • 2017 ACR/ARHP Annual Meeting
Enhanced IFN-γ STAT1 Signaling in CD4 T Cell Populations and Attenuated IL-2 STAT5 Signaling Contribute to the Pathogenesis of Rheumatoid Arthritis (RA)
Background/Purpose: Type I (IFN-α) and type II (IFN-γ) interferons are important mediators of autoimmunity. However, there is conflicting evidence regarding the contribution of IFN-γ to…Abstract Number: 86 • 2017 ACR/ARHP Annual Meeting
Regulation of Interleukin-1β Signaling By Inhibition of O-Glc-Nacase in Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: O-GlcNAcylation is an important post-translational modification of nuclear and cytosolic proteins involved in the cytokine signaling networks. Studies show both pro- and anti-inflammatory roles…Abstract Number: 621 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Background/Purpose: DAPSA score is a validated tool to measure disease activity states and response criteria, focusing on peripheral joint involvement in patients (pts) with PsA.1…Abstract Number: 626 • 2017 ACR/ARHP Annual Meeting
Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks
Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, was shown to be superior to placebo (PBO) in clinical responses and inhibiting the progression of structural joint…Abstract Number: 864 • 2017 ACR/ARHP Annual Meeting
IL-9-Producing Innate Lymphoid Cells – Keyplayers That Orchestrate Resolution of Chronic Inflammation in Arthritis
Background/Purpose: Transition from acute to chronic inflammation is a key step in the pathogenesis of inflammatory disease but incompletely characterized to date. Similar to the…Abstract Number: 970 • 2017 ACR/ARHP Annual Meeting
ACPA Activate Challenged Synovial Fibroblasts through a PAD Dependent Mechanism: A Potential Explanation of the “Second Hit Model” in RA
Background/Purpose: Anti-citrullinated proteins antibodies (ACPAs) injected in mice induce IL-8 dependent bone loss and arthralgia, but no synovial changes. We hypothesized that additional stimulus, sensitizing…Abstract Number: 1426 • 2017 ACR/ARHP Annual Meeting
Higher Levels of Interleukin-6 As Well As Soluble Interleukin-6 Receptor Leads to Worse Clinical and Radiographic Prognosis in Rheumatoid Arthritis Patients Treated with Tocilizumab
Background/Purpose: We have already reported that baseline levels of soluble interluekin-6 receptor (sIL-6R), target of tocilizumab, predicted response to tocilizumab treatment in rheumatoid arthritis (RA)…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 12
- Next Page »